Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy

T Alp Ikizler, P Toby Coates, Brad H Rovin, Pierre Ronco, T Alp Ikizler, P Toby Coates, Brad H Rovin, Pierre Ronco

Abstract

In this issue of Kidney International, the initial experience regarding the immunogenicity of prior coronavirus disease 2019 (COVID-19) infection and the response to the COVID-19 vaccines among patients on maintenance dialysis and kidney transplant recipients is summarized. Preliminary data suggest that there is durability of immune response after COVID-19 infection. Although immune response to the first dose of vaccine is less in infection-naïve patients than healthy individuals in both groups, after the second vaccine dose a significant portion of patients receiving maintenance dialysis develop robust antibody titers, whereas kidney transplant recipients show a less-strong immune response.

Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

References

    1. Ng J.H., Hirsch J.S., Wanchoo R. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98:1530–1539.
    1. Francis A., Baigent C., Ikizler T.A. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. Kidney Int. 2021;99:791–793.
    1. Clarke C.L., Prendecki M., Dhutia A. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int. 2021;99:1470–1477.
    1. Forbes S., Davari M., Gnanasampanthan S. Persistence of antibody response to SARS-CoV-2 in a cohort of haemodialysis patients with COVID-19 [e-pub ahead of print]. Nephrol Dial Transplant. Accessed April 15, 2021.
    1. Anft M., Blazquez-Navarro A., Paniskaki K. SARS-CoV-2–reactive cellular and humoral immunity in hemodialysis population. Kidney Int. 2021;99:1489–1490.
    1. Canas J.J., Starr M.C., Hooks J. Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit. Kidney Int. 2021;99:484–486.
    1. Torreggiani M., Blanchi S., Fois A. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. 2021;99:1494–1496.
    1. Billany R.E., Selvaskandan H., Adenwalla S.F. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients on hemodialysis: a call to arms. Kidney Int. 2021;99:1492–1494.
    1. Attias P., Sakhi H., Rieu P. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Kidney Int. 2021;99:1490–1492.
    1. Simon B, Rubey H, Treipl A, et al. Hemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls. MedRxiv. 10.1101/2021.03.26.21254259. Accessed April 15, 2021.
    1. Berar Yanay N., Freiman S., Shapira M. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients. Kidney Int. 2021;99:1496–1498.
    1. Boyarsky B.J., Werbel W.A., Avery R.K. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients [e-pub ahead of print]. JAMA. Accessed April 15, 2021.
    1. Benotmane I., Gautier-Vargas G., Cognard N. Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99:1487–1489.
    1. Benotmane I., Gautier-Vargas G., Cognard N. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021;99:1498–1500.
    1. Dogan M., Kozhaya L., Placek L. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. Commun Biol. 2021;4:129.
    1. Kristiansen P.A., Page M., Bernasconi V. WHO international standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397:1347–1348.
    1. Anderson E.J., Rouphael N.G., Widge A.T. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–2438.
    1. Edara V.V., Hudson W.H., Xie X. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination [e-pub ahead of print]. JAMA. Accessed April 15, 2021.
    1. Abayasingam A., Balachandran H., Agapiou D. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Rep Med. 2021;2:100228.
    1. Sokal A., Chappert P., Barba-Spaeth G. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201–1213.e1214.
    1. Le Bert N., Tan A.T., Kunasegaran K. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462.
    1. Dan J.M., Mateus J., Kato Y. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371
    1. Gleeson S., Martin P., Bedi R. Answering the call to action: rapid implementation of an in-center hemodialysis SARS-CoV-2 vaccination programme. Kidney Int. 2021;99:1238–1239.
    1. Chadban S.J., McDonald M., Wyburn K. Significant impact of COVID-19 on organ donation and transplantation in a low-prevalence country: Australia. Kidney Int. 2020;98:1616–1618.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever